亞輝龍(688575.SH):在腦機接口方面尚未有佈局
格隆匯8月7日丨亞輝龍(688575.SH)在互動平臺表示,公司始終堅持自主創新,以“學術引領,特色+常規”的差異化競爭策略,圍繞自身免疫、生殖健康、肝病檢測、糖尿病檢測、心腦血管檢測、中樞神經系統疾病檢測、腎病檢測等七大特色診斷及常規診斷業務領域,在中國或全球範圍內拿下了一個又一個創新診斷產品的首證。同時,積極挖掘包括AI技術在內的前沿科技在體外診斷產品中的應用潛力,打造從嚴肅醫療到健康管理、慢病管理,從院端到院外,軟件+硬件的全週期服務產品,持續提升公司的綜合競爭力,例如公司推出的抗核抗體(ANA)智能判讀系統、胰島功能標化評估數智平臺。但目前在腦機接口方面尚未有佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.